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Introduction
The progression of atherosclerosis usually consists of four stages and includes first stage (initiation), deposition of oxidative low density lipid (oxi-LDL) in the blood wall; second stage (fatty-streak formation), foam cell formation by recruited macrophages; third stage (advanced lesions), plaque formation; and fourth stage (complicated plaque), rupture of plaque and thrombus. [1] [2] [3] [4] [5] Once plaques rupture and detached thrombus enters the blood stream, then the major complications of atherosclerosis commence, like occlusive thrombus formation, stroke in the brain and heart infarction. [6] [7] [8] To diagnose the progression of vascular diseases, techniques that are capable of visualizing the blood stream to provide crucial information will be necessary to judge if a surgical operation is required or at which stage has the disease advanced before patients miss their opportunity for seeking early treatment.
Under many circumstances, when patients recognize their symptoms, severe atherosclerosis has already progressed and affected other tissues or functions of other organs. Therefore, prognostic investigation is urgently required for atherosclerosis imaging. 9 In general, atherosclerosis prognosis in clinics involves performing biochemical tests by taking patients' blood samples, which provide information on the level of cholesterol, homocysteine, as well as blood clotting factors. These quantitative results can give us the probability of atherosclerosis occurrence. However, where exactly atherosclerosis has arisen in our body or how serious the disease has progressed is still not clear clinically. Diagnosis of atherosclerosis based on molecular imaging will be able to present different stages of atherosclerotic lesions spatially. Medical examinations from the viewpoint of graphical images may also help clinicians prognose disease symptoms for early stage patients who display low detectable levels of cholestetol in the blood. Although various modalities for inflammatory imaging in the arterial wall have been developed pre-clinically and clinically, they are still not suitable for distinguishing between atherosclerosis-affected areas and normal unaffected tissues, like healthy blood vessels or other organs (e.g. parenchyma brain and cardiac muscles).
The molecular imaging targets in atherosclerosis have been well developed by association with the existence of macrophage as inflammatory immune cells. Since atherosclerosis is an inflammatory disease, 1 macrophages are involved in initiating and finalizing immune reaction by antigen-presenting and scavenger functions. In addition, characteristic changes caused by atherosclerosis like calcification on plaques have also been studied as one of the imaging targets. However, current targets that are expressed during the late stage of atherosclerosis still have clinical problems like toxicity/immunogenicity and also high background associated with non-specificity of probes in the arterial wall. The present status of molecular imaging in atheroscleososis is faced with the lack of specific probes capable of detecting only the target and the discovery of new targets to assist in prognosis during the early stage of atherosclerosis.
Here, we review current methodologies of atherosclerosis imaging aimed at macrophage-related, direct macrophage and non-macrophage targets. In addition, we also discuss potential new imaging target candidates for atherosclerosis imaging related to activated macrophage, biofilm and amyloid fibrils, which are recent emerging topics in atherosclerosis research.
Macrophage-related Targets
Atherosclerosis presents specific molecules dependent on the disease progression stages. Although there are many risk factors, the initiation stage of atherosclerosis inflammation may well be related to hyperlipidemia, which usually shows high concentrations of modified (oxidative) LDL in the blood. 1, 5 Under this environment, the endothelial cells which line the blood vessels will continuously come into contact with abnormal blood conditions, where endothelial cells will express several endothelial adhesion molecules, which are implicated in the process of mononuclear leukocyte rolling, firm adhesion and transmigration into blood vessels. Vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), P-and E-selectin are highly expressed and related to the recruitment of mononuclear leukocytes into the arterial wall during atherogenesis. 10 VCAM-1 is a receptor of the immunoglobulin family and bind to very late antigen-4 (VLA4) on monocytes and T lymphocytes, 10 making VCAM-1 a relevant molecule on the endothelia, macrophages and activated smooth She studied cellular and molecular biology during her Ph.D. studies until she joined Prof. Young-Tae Chang's lab in 2008 as a Research Fellow at the National University of Singapore, where she discovered a live cell imaging probe for stem cells as well as glucagon secreted in alpha cells. In 2010, she moved to the Singapore Bioimaging Consortium (SBIC) as a Senior Research Fellow. Currently, she is leading one of the internal projects at SBIC related to the development of pancreatic islet imaging probes to diagnose and treat diabetes. muscle cells during the initiation of atherogenesis. 11, 12 This is stage 1 where VCAM-1, ICAM-1, and P-selectin [13] [14] [15] [16] [17] [18] [19] (Table 1 ) are the main targets for imaging early stage atherosclerosis. At stage 2, fatty streaks formation by macrophages displays scavenger function during immune responses. In this regard, the imaging of macrophages as a target will be discussed in the next section. Stage 4 is defined by complicated plaque and induced plaque haemorrhage by αIIbβ3 integrin-related platelets, fibrin and proteolysis in the extracellular matrix by cathepsins and matrix metalloproteinases (MMP) of macrophages. Cathepsins and MMPs are highly expressed and localized in rupture-prone areas such as the fibrous cap, plaque shoulder and plaque rupture area. Therefore, cathepsins and MMP as macrophage-related molecules and primary imaging targets have been studied 3, [20] [21] [22] [23] [24] (Table 1 , Fig. 1 ). With these imaging targets, several non-invasive imaging equipment has been developed in cardiovascular medicine, which includes positron emission tomography (PET), singlephoton emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), ultrasound imaging and fluorescent molecular tomography (FMT). 25 These imaging modalities will be discussed in the "Current Imaging Techniques in Use" section.
As one of the macrophage-related targets, VCAM-1 was demonstrated as a target molecule by PET-CT imaging of apoE-/-mice. The tetrameric peptide 18 F-4V was developed as a PET-CT probe, whereas 99m Tc-labeled anti-VCAM-1 antibody (cAbVCAM105) and 99m Tc-labeled major histocompatibility complex 1-derived peptide (B2702p1) allowed SPECT/CT imaging against VCAM-1 expressed area in apoE-/-mice ( Table 1 , Fig. 1) . 18, 19, 26 Similarly, VCAM-1 ligand conjugatedGd was also reported for detecting early atherogenesis with MRI ( Table 1 , Fig. 1 ). 13 In addition, 18 F-FDG detects highly increased metabolic activity associated with atherosclerosis since the metabolic activities of cells are increased in the immune response area. 27, 28, 32 On the other hand, cathepsin protease activity and matrix metalloproteinases activity have been the main targets applied in fluorescent imaging, where diverse imaging probes were developed and used in apoE-/-mice. 2, 23 These adhesion molecule and extracellular matrix targets, which are parenchymal components of atherosclerosis, can increase the success of imaging and many studies have in fact shown their application in pre-clinical and clinical trials. However, these cathepsin protease activity and matrix metalloproteinases activity targeted molecules, as well as 18 F-FDG are stage 3 or stage 4 imaging molecules, making them more suited for diagnosis rather than prognosis. As these methods also have increased background signals in the case of atherosclerosis, it is necessary to increase the contrast so that accurate imaging information can be extracted. Diagnosis of atherosclerosis is an important part of clinical staging since it is necessary for accurate prescriptions, but for now, to prevent atherosclerosis, the prognosis imaging technique is expected to see the highest demand.
Direct Macrophage Targets
Although macrophages are at the center of immune responses in atherosclerosis formation, the target motives of developed probes are usually not the macrophage itself.
2,3,9,22 As mentioned earlier, macrophages infiltrate the tunica intima of the blood wall, engulf and deposit fat intracellularly. Subsequently, these macrophages change into foam cells and show activated macrophage characteristics [34] [35] [36] [37] during stage 2 of atherogenesis. In addition, foam cells are associated with glycolytic activity, oxidative LDL deposit and macrophage scavenger receptor-A (MSR-A) expression. 3 Activated macrophages also display functions against fatty streaks, 2,36,37 which start to form in blood vessels at stage 2. Therefore, activated macrophages can be targeted for atherosclerosis imaging in the early stages of the disease and may provide the possibility for prognosis in atherosclerosis development.
Since folate receptor 38 and peripheral benzodiazepine receptor 39, 40 are highly expressed on the surface of activated macrophages, they have been targeted for imaging. Folate-conjugated 99m Tc ( 99m Tc-EC20) and a selective ligand of translocator protein (TSPO), 11 C-PK11195 were developed and evaluated for atherosclerosis by SPEC/CT 38 and PET/CT, 30, 39 respectively (Table 1 , Fig. 1 ). In addition, macrophages show active phagocytotic functions. Taking advantage of this characteristic, super-paramagnetic iron oxide (USPIO) nanoparticle injection methods have been reported to increase T2 contrast in MRI, since macrophages in the inflamed area easily engulf iron oxide. [41] [42] [43] For PET/CT multimodality imaging with macrophage phagocytosis as the detection target, 64 Cu-TNP (tri-reporter nanoparticle; PET, MRI, fluorescence imaging by 64 Cu, monocrystalline iron oxide nanoparticle and Vivotag-680, respectively) has been developed and evaluated in atherosclerotic mice, but the labeling mechanism of 64 Cu-TNP is not known yet. 42 Similarly, zirconium-89 radiolabeled desferoxamine dextran nanoparticle ( 89 Zr-DNP) was recently developed for PET/MR imaging aimed at phagocytosis. The probe detects plaques by labeling monocyte/macrophage and neutrophils (Table 1, Fig. 1 ), but selectivity between monocyte, macrophage and activated macrophage has not been studied yet. 44 Although macrophages are the key factors of atherosclerosis formation, ironically, only several papers as mentioned above, have reported probes directly targeted at macrophages. As nonactivated macrophages are normally localized in tissues and organs of our body, to achieve selective imaging or to increase the contrast of imaging against the inflammation area, it is necessary for the developed probes to discriminate between non-activated and activated macrophages. However, it is very challenging to do so, and there are some limitations for developing activated macrophage-targeted probes.
Non-macrophage Targets
Although macrophages have a central function in atherogenesis, inflammation is related to diverse cells and surrounding tissues. This offers opportunity for non-macrophage targets to be used in atherosclerosis imaging.
For example, early stage atherogenesis shows oxidized low-density lipoprotein (oxi-LDL) deposits in sub-endothelial areas and this oxi-LDL plays a key role in the initiation, progression and destabilization of plaques in the blood wall. For oxi-LDL detection, antimalondialdehyde-modified LDL MDA2 antibody and gadolinium (Gd)-labeled micelles have been developed for animal imaging of atherosclerosis by MRI (Table 1) . 13, 45 At stage 3 of atherosclerosis, a fibrous cap starts to form as the advanced lesion in blood vessels and calcification is accentuated. At the same time, new vessels in blood vessels, known as vaso vasorum, are constructed in the adventitia of the blood wall, while αvβ3 integrin, a cell surface glycoprotein receptor related to neo-angiogenesis, becomes highly expressed in endothelial cells of vasa vasorum. In addition to that, vaso vasorum also recruits more leukocytes and rapidly induces progression of stage 4. Thus, αvβ3 integrin can be targeted for late-stage atherosclerotic imaging.
For αvβ3 detection, peptides containing the integrin-binding motif Arg-Gly-Asp (RGD) were developed and modified into 18 F-galacto-RGD (Table 1) for PET imaging. 46, 47 Recently, human carotid atherosclerosis imaging was evaluated by PET/CT multimodality using the 18 F-galacto-RGD probe. 48 During atherogenesis, arterial vessels undergo fibrosis and deposit minerals in the plaque area. This calcified area in atherosclerotic plaque is prone to rupture and microcalcification in the fibrous cap also induce micro-fractures that can lead to plaque rupture. 49 The calcification process provides probes like bisphosphonate-conjugated imaging agent (OsteSense750) the opportunity to give strong signals, which can be doubleconfirmed by CT imaging. Early microcalcification though cannot be detected by CT; this is possible by bisphosphonateconjugated agent, since it is capable of detecting areas with microcalcification and osteoblastic phenotype cells in atherosclerosis. 50 Fibrin, which is related to coronary artery clots and thrombosis, has been demonstrated as an imaging target in the late stage of atherosclerosis. This was done by MRI in a swine model using EP-2104R-Gd, which is a fibrin-specific contrast agent (EP-2104R, EPIX Pharmaceuticals, Lexington, MA). 51 Separately, cell death was also evaluated as a target using 99m Tc-labeled annexin V, which detects apoptotic cells of macrophages or smooth muscle cells by SPECT (Table 1) . [52] [53] [54] Although these non-macrophage-related targets can reveal atherosclerotic areas by imaging, nonetheless, limitations related to high background in vivo or late-stage detection still pertain.
New Target: Biofilm
Atherosclerosis is a complicated inflammation disease. It is hard to be explained only by factors like LDL-cholesterols and macrophages. 55 Espinola-Klein and colleagues provide evidence of other factors, such as herpes simplex virus, cytomegalovirus, Epstein-Barr virus, Hemophilus influenza, Chlamydia pneumonia, Mycoplasma pneumonia, or Helicobacter pylori, which can be important factors in atherosclerosis. 56 Also, several kinds of bacteria related with cardiovascular disease have been reported, where some of them have been isolated from plaques directly. 57 For example, periodontal bacteria were detected in coronary stenotic artery plaque by PCR and 16s rRNA detection, which is a component of the 30s small subunit of prokaryotic ribosomes. 58, 59 It is hypothesized that bacteria penetrate into blood vessels directly and circulate through the blood stream, where at some stage bacteria invade the endothelium and make biofilm, leading to endothelial dysfunction, inflammation and atherosclerosis formation. 60 Usually, these bacteria were infected from surgery procedures, such as aortic valve implantation, and catheter insertion. Also, oral bacteria, which consist of diverse bacterial species, may also enter the circulatory system through bacteremia, mainly by dental manipulations like scaling, extraction and even flossing. [61] [62] [63] It was reported that periodontal bacteria are associated with atherosclerotic vascular disease 64 and several studies also reported that bacterial infections increase the likelihood of atherosclerosis or coronary artery disease. [65] [66] [67] During circulation in the blood stream, planktonic bacteria can easily make biofilm, which is a surface-associated structure of communal microorganisms encased within a secreted matrix of exopolysaccharides 56 and attach onto surfaces as dense and heterogeneous populations. Cells attached on the surface become more resistant to anti-microbial reagents and immune responses. 68 This phenomena may allow atherosclerosis to be visualized by bacteria or biofilm if suitable techniques become available.
To monitor infected bacteria/biofilm, in previous reports bacterial pathogens were modified to express bioluminescence. After bacterial infection, soft tissue, bladder, and urinary tissues were monitored based on luminescent signals. 70 Also, in vivo imaging of tuberculosis progression was tried in mice after infection of an M. tuberculosis strain carrying a red-shifted derivative of the firefly luciferase gene. 71 Recently, MRI imaging of S. aureus labeled with iron oxide particle was developed for detection of S. aureus colonies in infection models. 72 However, these methods are not suitable for clinical application because they involve pre-labeled/modified bacteria, where bacteria tracking in animal models were visualized by luminescence and MRI. For biofilm studies, concanavalin A (Con-A; Concanavalin A-Alexa Fluor® 488) and BacLightTM Green stain methods are usually used for detecting biofilm formation areas. 68 The BacLightTM is a non-nucleic acid labeling reagent, which is already used to detect a variety of different bacteria species, whereas Con-A is a lectin-conjugated compound, which selectively binds to glucose and mannose residues of cell wall polysaccharides. 68 In the apoE-/-mouse model, the atherosclerosis area shows the deposition of mannose-binding lectin (MBL), which has the opsonin function as complement components. 73, 74 Under this environment, lectinconjugated microbubble micelle were developed and applied for biofilm detection in vitro by high-frequency scanning acoustic microscopy, 75 but there are no established methods for in vivo biofilm imaging in atherosclerosis so far. Collectively, these factors show some possibility of biofilm imaging by mannose residue target and lectin-conjugated compounds or nanoparticles, and there are also opportunities for developing bioimaging probes targeted at biofilm components itself such as DNA, protein and mainly polysaccharides that are self-produced. With this in mind, the development of biofilm imaging probes as one of the putative targets can show new insight into the biofilm process and atherosclerosis imaging.
New Target: Amyloid Fibrils
Amyloid fibrils arise when misfolded proteins aggregate into highly-ordered structures. 76 The accumulation of amyloid fibrils along with some non-fibrillar constituents within amyloid plaques is associated with the pathogenesis of several human degenerative diseases, including Alzheimer's disease, Parkinson's disease and variant Creutzfeldt-Jakob disease. Whilst the association of amyloid with these diseases is well recognized, an emerging theme in amyloid research is the increased deposition of amyloid fibrils within artery walls in association with aging, and the potential role that amyloid fibrils play in cardiovascular disease. 77, 78 It has been reported that as much as 60% of aortic atherosclerotic lesions contain fibrillar proteins.
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Numerous amyloid-forming proteins that have been identified in the atherosclerotic intima include many members of the plasma apolipoprotein (apo) family: apoA-I, A-II, A-IV, C-II, E, serum amyloid A (SAA) and alphasynuclein. 77, 82, 83 An important class of serum proteins, apolipoproteins are found embedded in the lipid surface of lipoprotein particles, like low-density lipoprotein (LDL) and high-density lipoprotein (HDL), and together these proteinlipid complexes transport triacylgycerols, cholesterol and phospholipids in the blood stream. [84] [85] [86] The propensity of apolipoproteins to form amyloid fibrils may be attributed to their common structural and conformational properties. 87, 88 Apolipoproteins contain a high proportion of class A amphipathic α-helical domains, which mediate their binding to lipoprotein surfaces. Under lipid-free conditions, however, their helical content diminishes and their conformational stability beomes significantly compromised. This leads to the development of an amyloidogenic conformation and subsequently the formation of amyloid fibrils. 87, 88 Substantial evidence indicates that amyloid deposits, together with oxidative processes and inflammation contribute to the pathogenesis of atherosclerosis. 89, 90 In fact, several products of cholesterol oxidation have been detected in human atherosclerotic tissue. 91 This includes the principle product of cholesterol ozonolysis, 3-hydroxy-5-oxo-5,6-seconcholestan-6-al (a ketoaldehyde cholesterol derivative, referred to as KA), which has been shown to promote apoC-II fibrillogenesis in vitro. It does so by inducing changes in the secondary structure of monomeric apoC-II, hence, driving apoC-II self-association and fibrillization. 92 Furthermore, oxysterols derived from oxi-LDL activate the nuclear receptors, liver X receptor (LXR)-α and -β that regulate expression of the apoE, C-I, C-II, and C-IV gene cluster. 93 Expression of this gene cluster in lesional macrophage foam cells is thought to increase secretion of lipid-free apolipoproteins into the sub-endothelial space, where they would be predisposed to amyloidogenesis. Indeed, apoC-II was shown to co-localize with serum amyloid P, the marker for amyloid fibrils, in human atherosclerotic lesions 94 and is detected in the proximity of macrophage foam cells. 95 Inflammatory processes within atheroma increase the levels of SAA that can competitively displace apoA-I from HDL particles, leading to elevated local concentrations of lipid-free apoA-I, which in turn increases the likelihood of amyloid formation. 81 In addition, methionine oxidized apoA-I is also likely to be elevated at these sites, further promoting fibril formation. 96 Taken together, an amplification cycle may develop, where amyloidogenesis is continuously triggered as inflammatory stress stimulus initiates the production of KA or other oxidized metabolites, further exacerbating inflammation.
The findings that fibrillar aggregates can trigger an immune response by activating macrophages further highlighted the pathological importance of amyloid deposits in atherosclerosis. 95 Macrophage pattern recognition receptors, such as scavenger receptors and the RAGE receptors, recognize amyloid fibrils and mediate an innate immune response to these modified selfligands. 97 Interestingly, many of these multi-ligand receptors already have proposed roles in atherosclerosis and are upregulated in atherosclerotic lesions. 93 Several members of the scavenger receptor family, including scavenger receptors A, BI and CD36, can bind amyloid and are expressed on lesional cells like macrophages, endothelial cells, and vascular smooth muscle cells. 95 In particular, CD36 recognizes and take up amyloid fibrils, which then initiates a pro-inflammatory signaling cascade that promotes leukocyte recruitment, as well as activation and secretion of inflammatory mediators. All of these are key features that lead to lesion development. Oxidized-LDL and non-fibrillar species, on the other hand, failed to elicit the same effect, strongly indicating that the activation of the macrophage response is dependent on amyloid species. Furthermore, the finding that Aβ amyloid also initiates macrophage inflammatory responses suggests that this may well be a general property of amyloid fibrils. 98 In addition, amyloid aggregates have been shown to up-regulate the production of matrix metalloproteinases (MMPs) by macrophages, which are known to degrade the fibrous proteins within the protective cap of atherosclerotique plaques. 101 Vulnerable plaques, or atherosclerotic plaques that are prone to rupture are characterized by a large lipid core and a thin fibrous cap that breaks easily. Smooth muscle cells play an important role at stabilizing this cap, as they synthesize the fibrous components within the cap. Hence, another destabilizing effect involves the discussion that the number of smooth muscle cells may be reduced by amyloid fibrils, 102 and subsequently the reduction of cap size, since substantial evidence indicates a link between these protein aggregates and cell death. 103 Given that the combined parameters explain the common and specific association of amyloid deposits with atherosclerotic plaque tissue, we propose targeting the occurrence of amyloid fibrils in atherosclerotic plaques as a plausible new imaging candidate. At present, Congo Red (CR) staining is the routine method applied for the detection of amyloid fibrils. CR staining is based on the characteristic β-sheet configuration of amyloid fibrils, which exhibits amorphous pink deposits at light microscopy and apple-green birefringence under polarizing light microscopy. Alternatively, thioflavin-T (ThT) stain can be used, which produces yellow-green fluorescence. However, both CR and ThT staining can only confirm occurrence of amyloid fibrils in general, indistinguishable of the amyloidogenic protein origin. Furthermore, CR and ThT staining are not useful for diagnosis or prognosis purposes, since both can only be done on postmortem tissue. By far, more progress has been achieved to non-invasively image amyloid plaque deposition associated with neurodegenerative diseases, where analogs of CR and ThT have been developed as probes that are compatible with in vivo imaging. In comparison, there is very little development in the area of imaging amyloid fibrils for the study of atherosclerosis. On the other hand, the fact that only about half of the complicated atherosclerotic plaques contained amyloid may give the impression that these misfolded protein aggregates cannot be pathogenically important in vascular inflammation and the promotion of atherosclerosis. It is also possible that the most toxic species may not be the fibrils, but the relatively soluble and diffusible pre-amyloidogenic species, as supported by an increasing body of literature arising from Alzheimer's disease studies, which implicate that damages in brain functions occurred before the appearance of amyloid deposits. 104 The same may apply for atherosclerosis, since amyloid deposits are seen almost exclusively in advanced plaques, which is parallel with the notion that lesions take time to develop. In fact, an age-related increase in localized amyloid deposits within the artery wall has been described, where amyloid deposits that have been detected in the aortic media of 97% of atherosclerotic patients are aged 50 years and over. 105 Further studies on the folding and self-assembly of apolipoproteins in atherosclerotic plaques may provide crucial insight into this potentially significant aspect of the atherogenic process.
Hence, development of an alternate putative imaging agent targeted not only at amyloid fibrils, but also at the earlier intermediary, prefibril species of lipid-free apolipoproteins, will be able to shed light on the potentiating roles of these species in atherosclerosis.
Current Imaging Techniques in Use
Once the detection targets are decided, molecular imaging relies on diverse imaging techniques like Ultrasound, CT, SPECT, PET, MRI and FMT. 25 Each equipment has its own characteristics for atherosclerosis imaging. For example, CT and MRI usually show only anatomical information, whereas SPECT and PET usually detect only functional information. SPECT and PET require the use of radioactive probes, whereas MRI has a limitation in detecting small arteries and when contrast medium is applied may have some side effects. 9, 25 FMT and newly developed optoacoustic tomography 107 using near-infrared fluorescent probes do not require the use of radiation, but have limited spatial resolution, limited penetration depth and are restricted to animal studies, as well as ex vivo human tissue in their current states. To obtain accurate imaging information for diagnosis and prognosis, both anatomical and functional information will be necessary. Hence, for human application and clinical trials, multimodality imaging equipment have been developed and primarily used. This includes PET/CT, PET/ MRI, SPECT/CT or SPECT/MRI. 108 With such combination equipment, we can obtain anatomical information from MRI or CT and functional information from PET or SPECT with probes for accurate atherosclerosis imaging.
The developmental strategy of diverse imaging probes should be changed in accordance with the imaging equipment, since the workings of PET, SPECT and MRI imaging techniques are based on their own imaging principles: positron emission, single photon emission and T1/T2 contrast, respectively. Using a PET imaging probe, 11 C-PK11195, as an example, this radioisotope probe consists of a target-binding motif (PK11195) and a reporting motif ( 11 C), which are conjugated for PET/SPECT functional imaging. Prior to clinical and pre-clinical trials (animal experiments), target-binding probes are usually developed by an in vitro and cell-based screening system. For easier selection during screening, a fluorescent library as the binding motif can be used and applied. 109 Based on our experience, probes selected by in vitro screening have about 10% probability to proceed to a cell-based experiment. From there, another 10% of probes survive, and finally probes that are narrowed down by animal experiments can detect specific targets with around 1% probability. So, all in all, only 0.1% of the probes from initial screening can survive for the final target imaging in animal models. During the progress from cell-based to animal experiments, many toxicological and non-specific probes can be easily ruled out. Fortunately with nuclear imaging techniques, due to the high sensitivity of radioisotopes, we can decrease the dose of imaging probes. After developing the target-binding portion of the probe, as in the case of PK11195, the probe can then be converted into a reporting motifconjugated version like 11 C-PK11195. At this stage, some putative probes can also be excluded. In Table 1 , we summarized atherosclerosis targets in reported pre-clinical trials, which consist of diverse modalities and diverse probes. The probes of the mentioned categories, including macrophage related targets, direct macrophage targets and non-macrophage targets, have been much studied and evaluated with atherosclerosis animal model and ex vivo human samples. Although there are 14 subcategories (Table 1) , only a handful of probes like 18 FDG, 11 C-PK11195, 18 F-galacto-RGD and 99m Tc-Annexin V have successfully been applied for atherosclerosis imaging clinical trials (Fig. 2) . 20, [29] [30] [31] 40, 48, 54 Clearly, more new targets as well as new probes for atherosclerosis imaging are needed.
New Probe Development
With new putative targets, the development of accurate imaging probes will be the next step for prognosis and diagnosis of atherosclerosis. For example, macrophage targets will be able to show more specific imaging and reveal early stages of atherosclerosis. However, it has been difficult to develop specific atherosclerotic macrophage probes against nonatherosclerotic areas since macrophages are localized everywhere in our body. To achieve more accurate imaging, we suggest the development of activated-macrophage targeted probes. Activated macrophages are divided into M1 and M2 subtypes, which are dependent on the related helper T cells. M1 macrophages are involved in acute inflammation and proinflammation functions, whereas M2 macrophages are related to chronic inflammation and anti-inflammation functions. 5, 106, 110 Both M1 and M2 macrophage reactions are related to and have been observed in atherosclerotic immune responses. 111, 112 To discriminate between these subtypes and non-activated (resting) macrophages, several surface markers were discovered. For example, CD4, CD16/32 and CD86 are the surface markers of M1 activated macrophages, while CD206 and arginase 1 are markers of M2 activated macrophages. 106, 110, 111 Macrophages in atherosclerosis function as scavengers in removing fatty acid deposits. This is a pro-inflammation response and foam cells have similar characteristics of activated M1 macrophages. 5, 110, 111 Therefore, the development of binding probes against M1 surface markers can be one of the putative target molecules. In addition, by using ligands or probes against CD16/32 or CD86 surface markers, the development of ligand/probe-conjugated and radioisotope conjugated nanoparticles (multiple conjugate nanoparticles) can be one of the methodologies for MRI or PET atherosclerosis imaging. With target-oriented fluorescent library (TOFL), the ligands of M1 or M2 surface marker can be searched and can be developed in cold chemistry for cell and animal experiments.
Furthermore, through radioisotope modification in the reporting motif, atherosclerosis imaging can be possible in animal experiments and clinical trials. In addition, new putative targets of atherosclerosis that are non-macrophage-related, such as biofilm and amyloid fibrils, have been suggested as potential targets. Although bacteria/ bacteria film (biofilm) [113] [114] [115] and amyloid fibrils [69] [70] [71] are known to be components of atherogenesis, thus far there have been no development of non-invasive imaging techniques that are targeted at either biofilm or amyloid fibrils in the area of atherosclerosis imaging. Thus, it is clinically necessary to develop a non-invasive imaging modality to evaluate biofilm and amyloid load quantitatively, to monitor disease progression and response to treatment. Con-A can be used for detecting biofilm but this method is only for in vitro systems and it is necessary to discover new targets in biofilm and develop new probes that can discriminate biofilm against other tissues or organs. For the detection of amyloid fibrils, great progress has been made to non-invasively image Aβ plaque deposition in the brain of Alzheimer's patients using PET, which has resulted in the approval of 18 F-Florbetapir by the US Food and Drug Administration (FDA). 116 It is likely that similar tracers may have the potential to visualize amyloid fibrils found in arterial plaques. Concurrently, alternate imaging strategy targeted at earlier oligomeric, pre-fibril species can be developed, in parallel with an increasing shift of focus in the field, where more evidence points to these intermediary assemblies as the toxic species.
In the event that even we already know the target of binding motif like the mentioned molecules, the probability of in vivo animal application and clinical trials with developed probes is still very low. As an alternate approach, we have developed the diversity oriented fluorescent library (DOFL), which is generated by combinatorial modification of organic fluorescent scaffolds, and has binding motif and chromophore at the same time in itself. The DOFL approach has been successfully applied for sensing small molecules, cell imaging and animal imaging. [117] [118] [119] [120] For example, high-throughput screening for direct activated macrophage targets by DOFL can be done with endothelia, smooth muscle cells, non-activated macrophages, and activated macrophages stimulating atherosclerotic environments, where only activated macrophage-stained probes will be selected for animal experiments. After the modification of selected probes with radioisotope labeling for example, non-invasive imaging multimodalities can be applied for atherosclerotic prognosis and diagnosis. The development of biofilm and amyloid fibril selective probes can also be applied with this approach. Although we do not know the accurate binding target against the developed probes with the DOFL approach, we can discriminate specific cells or proteins against its surrounding environment components and also develop radioisotope labeled version of probes for multimodality imaging.
Conclusions
Our understanding of molecular imaging targets and probes in atherosclerosis has progressed remarkably over the past few years. Current imaging targets of atherosclerosis are involved in inflammation, which is important at many stages of atherosclerotic plaque development.
The features of atherosclerotic plaques exemplify that atherosclerosis as a complex disease, and many components of the vascular, metabolic, and immune systems are linked in this process. Although the typical targets correlated with macrophagedependence have been taken advantage of in conventional molecular imaging of atherosclerosis, the sensitivity of existing probes are still short of detecting specific targets and certain stages of atherosclerosis.
Vulnerable plaques with a large lipid pool, a thin fibrous cap and many inflammatory cells in the blood vessel can cause severe complications to the patient when plaques rupture. Although there are several imaging probes or methodologies for clinical diagnosis, the development of new target imaging probes for prognosis, like detecting "prone to rupture areas" will be necessary to prevent further progression of atherosclerosis and complications related to the disease. In summary, we propose the detection of activated macrophages, bioflim and amyloid fibrils as new targets for molecular imaging of "prone to rupture areas" in atherosclerosis. In addition, the application of DOFL as a new approach will aid the development of accurate target probes to detect atherosclerotic areas by functional noninvasive imaging. 
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